Clinical Trials Logo

Neovascularization, Pathologic clinical trials

View clinical trials related to Neovascularization, Pathologic.

Filter by:

NCT ID: NCT01229540 Terminated - Clinical trials for The Mechanism of Retinal Neovascularization of Diabetic

Clinical Research on Retinal Neovascularization of Diabetic Retinopathy

Start date: n/a
Phase: N/A
Study type: Interventional

Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.

NCT ID: NCT01122511 Terminated - Clinical trials for Age-Related Maculopathy

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration

NCT ID: NCT01021956 Terminated - Clinical trials for Macular Degeneration

Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Start date: June 2010
Phase: Phase 2
Study type: Interventional

The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD). The drug product is activated in patients by exposure to light at a specific wavelength ("Vascular Targeted Photodynamic therapy", "VTP"). The exploratory objective is to assess whether it is possible to delay or reduce the requirement for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12 weeks after VTP. All subjects will have a 52 weeks safety follow up telephone call (Not for Adverse Events (AEs) collection).

NCT ID: NCT00915590 Terminated - Clinical trials for Corneal Neovascularization

Topical IL-1-Ra for Treatment of Corneal Neovascularization

Start date: April 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.

NCT ID: NCT00902785 Terminated - Clinical trials for Age-related Macular Degeneration (AMD)

A Study Of Early Markers Of Choroidal Neovascularization

Start date: March 2008
Phase: Phase 4
Study type: Observational

Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of intervention.

NCT ID: NCT00766337 Terminated - Clinical trials for Age-Related Macular Degeneration

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

EMERALD
Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

NCT ID: NCT00737321 Terminated - Wounds and Injuries Clinical Trials

Mechanisms Regulating Wound Vascularization

Start date: August 2008
Phase:
Study type: Observational

This pilot study is designed to assess the impact of ischemia/ diminished wound vascularization and stress on wound healing by comparing patterns of gene expression in specific cell types critical to wound healing biology, e.g. macrophages or endothelial cells.

NCT ID: NCT00712491 Terminated - Clinical trials for Age-related Macular Degeneration

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Start date: September 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.

NCT ID: NCT00509548 Terminated - Clinical trials for Macular Degeneration

Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD

Start date: July 2007
Phase: Phase 2
Study type: Interventional

Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina. The build-up of fluid (edema) under the macula can distort vision or cause vision loss. TG100801 is a topical (eye drop) therapy that has been shown to inhibit ocular angiogenesis, vascular leak, and inflammation in laboratory studies. The primary purpose of this pilot study is to evaluate the ability of topical administration of TG100801 to reduce the amount of fluid in the retina in patients with AMD following 30 days of treatment. An additional objective is to evaluate the safety of TG100801 in patients with AMD.

NCT ID: NCT00433017 Terminated - Clinical trials for Macular Degeneration

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Start date: May 2007
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration